Eiger to discontinue hepatitis drug study over safety concerns
Send a link to a friend
 [September 13, 2023]
(Reuters) -Eiger BioPharmaceuticals Inc said on Tuesday it would
discontinue a late-stage study testing its experimental drug to treat
the most severe form of viral hepatitis, due to safety concerns.
The decision follows the recommendation of an independent data and
safety monitoring board after it observed deterioration in liver
function in four patients during a quarterly safety review.
The drug candidate, peginterferon lambda, was being tested in patients
with chronic hepatitis delta (CHD).
[to top of second column]
|
 "The study discontinuation is
disappointing, especially for patients with chronic hepatitis delta
who have limited treatment options," said Eiger CEO David Apelian.
The company said it will work closely with the U.S. Food and Drug
Administration and trial investigators to conduct an orderly
termination of the study.
(Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
